Table 1.
Rotavirus vaccine effectiveness studies.
| Country | Vaccine/year introduced | VE against RV hospitalization (full vaccination course, Vesikari > 11) | Change in VE between age <12 mo to >12 mo |
|---|---|---|---|
| Nicaragua | 2006 - RotaTeq | Overall VE all – 45% (25–59%) (G2P4-63%, G1P8-42%; G3P8-23%) | Yes (statistically significant) |
| 6–11 mo – G2- 68%; G1- 71%; G3 - 40% | |||
| >12 mo - G2- 60%; G1- 25%; G3 - 22% | |||
| VE decline with age/genotype | |||
| Rwanda | 2012 - RotaTeq | Overall VE all – 75% (31–91%) (6–36 mo) | No |
| 6–11 mo – 65% (−80 to 93%) | |||
| >12 mo – 81% (25–95%) | |||
| Bolivia | 2008 – Rotarix | Overall VE all – 59% (37–73%) (2–59 mo) | |
| 2–11 mo – 76% (50–89%) | |||
| >12 mo – 45% (0–70%) | |||
| Malawi | 2012 – Rotarix | Overall VE all- 58.3% (20–78%) (0–59 mo) | Yes (statistically significant) |
| (G1P8 – 82.1 (44–94); G2P4 – 34.9% (−135 to 82%) | |||
| <12 mo – 70.6% (33–87%) | |||
| 12–23 mo – 31.7% (−140 to 80%) | |||
| 24–31 mo – 28.8% (−147 to 79%) | |||
| Moldova | 2012 – Rotarix | Overall VE all – 79% (62–88%) (6–59 mo) | Yes (not statistically different) |
| 6–11 mo – 84% (67–92%) | |||
| 12–23 mo – 46% (−16 to 75%) | |||
| Armenia | 2012 – Rotarix | Overall VE all – 62% (36–77%) (6–23 mo) | No |
| 6–11 mo - 68% (24–86%) | |||
| 12–23 mo – 60% (20–80%) | |||
| Botswana | 2012 – Rotarix | Overall VE all - 54% (23–73%) (4–59 mo) | No |
| 4–11 mo – 52% (8–75%) | |||
| >12 mo – 67% (8–89%) |